Mark Brosius Sells 215 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 215 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $549.06, for a total transaction of $118,047.90. Following the completion of the sale, the senior vice president now owns 1,768 shares in the company, valued at $970,738.08. This represents a 10.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Mark Brosius also recently made the following trade(s):

• On Wednesday, June 4th, Mark Brosius sold 215 shares of Intuitive Surgical stock. The shares were sold at an average price of $552.07, for a total transaction of $118,695.05.
• On Friday, May 16th, Mark Brosius sold 20 shares of Intuitive Surgical stock. The stock was sold at an average price of $563.81, for a total transaction of $11,276.20.
• On Wednesday, May 14th, Mark Brosius sold 22 shares of Intuitive Surgical stock. The shares were sold at an average price of $563.00, for a total value of $12,386.00.
• On Monday, May 12th, Mark Brosius sold 22 shares of Intuitive Surgical stock. The stock was sold at an average price of $551.97, for a total value of $12,143.34.
• On Friday, March 7th, Mark Brosius sold 489 shares of Intuitive Surgical stock. The shares were sold at an average price of $533.18, for a total value of $260,725.02.

Intuitive Surgical Price Performance

Shares of ISRG opened at $557.95 on Thursday. The company’s 50-day moving average is $519.52 and its 200-day moving average is $538.95. The firm has a market capitalization of $199.98 billion, a PE ratio of 87.04, a PEG ratio of 5.85 and a beta of 1.67. Intuitive Surgical, Inc. has a fifty-two week low of $405.08 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion for the quarter, compared to analyst estimates of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same quarter in the prior year, the business earned $1.50 EPS. Analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intuitive Surgical

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sycomore Asset Management grew its holdings in Intuitive Surgical by 27.4% in the 4th quarter. Sycomore Asset Management now owns 18,945 shares of the medical equipment provider’s stock valued at $9,214,000 after buying an additional 4,079 shares in the last quarter. Castleark Management LLC grew its stake in shares of Intuitive Surgical by 3.4% in the fourth quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider’s stock valued at $47,221,000 after acquiring an additional 2,990 shares in the last quarter. Truist Financial Corp increased its position in Intuitive Surgical by 3.0% during the fourth quarter. Truist Financial Corp now owns 248,092 shares of the medical equipment provider’s stock worth $129,494,000 after acquiring an additional 7,298 shares during the period. Global X Japan Co. Ltd. raised its stake in Intuitive Surgical by 9.8% in the 4th quarter. Global X Japan Co. Ltd. now owns 46,289 shares of the medical equipment provider’s stock worth $24,161,000 after purchasing an additional 4,140 shares in the last quarter. Finally, Northeast Investment Management boosted its holdings in Intuitive Surgical by 3.1% in the 4th quarter. Northeast Investment Management now owns 89,170 shares of the medical equipment provider’s stock valued at $46,543,000 after purchasing an additional 2,685 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ISRG. Evercore ISI cut their price target on shares of Intuitive Surgical from $510.00 to $470.00 and set an “in-line” rating on the stock in a research note on Wednesday, April 23rd. BTIG Research set a $560.00 price objective on shares of Intuitive Surgical and gave the stock a “buy” rating in a report on Monday, April 14th. Royal Bank of Canada reduced their target price on shares of Intuitive Surgical from $630.00 to $605.00 and set an “outperform” rating for the company in a research note on Wednesday, April 23rd. Barclays lowered their target price on Intuitive Surgical from $684.00 to $635.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Finally, Piper Sandler reduced their price objective on Intuitive Surgical from $670.00 to $575.00 and set an “overweight” rating for the company in a research report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $596.05.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.